Antibody co-targeting of DCs.

摘要

An effective vaccine contains immuno-dominant antigens and adjuvants that are processed by in vivo DCs to elicit humoral and cellular (effector and memory) immunity. Uncoupling DCs and their adjuvants via route or scheduling of administration may reduce or eliminate the desired immune response. In this issue of Blood, Tacken et al show for the first time that in vivo DC vaccination benefits from co-targeting antigen with adjuvants via nanometer sized particulate carriers (see figure).